Globus Medical Inc. (GMED)
Globus Medical, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- GMED
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.
Investors who lost money on Globus Medical, Inc. should contact Levi & Korsinsky about an ongoing investigation - GMED
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.
Globus Medical, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - GMED
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.
GMED STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm!
NEW YORK CITY, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.
GMED ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Globus Medical, Inc.
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.
ATTENTION GMED SHAREHOLDERS: Investors who lost money on Globus Medical, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Globus Medical, Inc. ("Globus Medical, Inc.") (NYSE:GMED) concerning possible violations of federal securities laws. In a filing with the U.S. Securities and Exchange Commission on August 13, 2024, Globus disclosed that "[o]n July 16, 2024, Globus Medical, Inc. received a warning letter from the U.S. Food and Drug Administration (the ‘FDA') following an inspection of our facilities in Audubon, Pennsylvania.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") (NYSE:GMED). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
GMED INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Globus Medical, Inc. and Encourages Investors to Contact the Firm!
NEW YORK CITY, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. ("Globus Medical" or "the Company") (NYSE:GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/GMED.
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Globus Medical (GMED) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
Globus Medical, Inc. (GMED) Q2 2024 Earnings Call Transcript
Globus Medical, Inc. (NYSE:GMED ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Brian Kearns - SVP, Business Development and IR Daniel Scavilla - President and CEO Keith Pfeil - COO and CFO Conference Call Participants Matthew Miksic - Barclays Vikramjeet Chopra - Wells Fargo Shagun Singh - RBC CM Steve Lichtman - Oppenheimer David Saxon - Needham & Company Matthew O'Brien - Piper Sandler Jason Wittes - ROTH Matthew Blackman - Stifel Ryan Zimmerman - BTIG Ravi Mishra - Truist Craig Bijou - BofA Operator Welcome to Globus Medical's Second Quarter 2024 Earnings Call. At this time, all lines will be on mute and a Q&A session will be held after the prepared remarks.
